Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 clinical trial of S 221237 in healthy volunteer.

Next Previous
Trial Profile

A phase 1 clinical trial of S 221237 in healthy volunteer.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs S-221237 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Servier

Most Recent Events

  • 20 Dec 2024 According to an Oncodesign Precision Medicine media release, the company announced the reacquisition of the rights to its OPM-201 program in the treatment of Parkinson's disease from Servier laboratories. Final Phase 1 results are expected in the second quarter of 2025.
  • 18 Apr 2024 According to an Oncodesign Precision Medicine media release, company has completed this phase I trial in healthy volunteers this year.
  • 18 Apr 2024 Status changed from recruiting to completed, according to an Oncodesign Precision Medicine media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top